胆汁酸アナログ 肝繊維症
C Daniel De Magalhaes Filho1, Michael Downes1, Ron Evans1
1Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Cell
|August 13, 2016
まとめ
Ocalivaは,合成胆酸アナログであり,ウルソデオキシコール酸 (UDCA) に反応しない患者で,一次胆道胆炎を効果的に治療します. このFXRアゴニストは,自己免疫性肝疾患の管理に代替手段を提供している.
科学分野:
- ヘパトロジー
- 薬理学について
- 免疫学
背景:
- 原発性胆管炎 (PBC) は慢性的な自己免疫性肝疾患である.
- ウルソデオキシコール酸 (UDCA) は従来の治療法ですが,一部の患者は不十分な反応または不耐性を示します.
- 核胆酸受容体ファルネソイドX受容体 (FXR) は胆酸ホメオスタシスに作用する.
研究 の 目的:
- 主要胆管炎の治療におけるOcaliva (オベチコール酸) の有効性を評価する.
- UDCAに耐受できないまたは反応しないPBC患者の治療選択肢としてOcalivaを評価する.
主な方法:
- オカリバはFXRを標的にする合成胆酸アナログです.
- 主要な胆管炎の患者に対するOcalivaの投与
主要な成果:
- Ocalivaは,原発性胆管炎の治療に有効であることが示されています.
- Ocalivaは,UDCA治療に耐性のあるPBC患者のための治療選択肢を提供します.
結論:
- Ocalivaは,一次性胆管炎の有効な治療法である.
- オカリバは,従来の治療が失敗した自己免疫性肝疾患の患者にとって貴重な治療の代替手段です.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
313
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
313
Ultrasound II: Endoscopic Ultrasound and FibroScan
998
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
998
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Hepatic Drug Excretion: Enterohepatic Cycling
3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
325
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
325


